FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 321:636-641 September 7, 1989 Number 10 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

The early discrimination of clinically aggressive breast cancer from indolent disease would be clinically useful. Some human breast cancers express haptoglobin-related protein (Hpr), the HPR gene product, or a substance that shares epitopes with it. We retrospectively examined the association between the expression of Hpr and the recurrence of cancer in 70 patients with early breast cancer (Stage I or II) treated by mastectomy from 1977 through 1985, using immunohistochemical analysis of routinely processed paraffin-embedded tissue and evaluating it without knowledge of the patients' status. The expression of Hpr epitopes was associated with earlier recurrence according to life-table analysis (P less than 0.0002). Progesterone-receptor status (determined in 64 patients), tumor size, clinical stage, axillary-lymphnode status, mitotic index, and tumor necrosis also predicted recurrence, but multivariate analysis showed that Hpr-epitope expression was an independent prognostic factor. Since both Hpr status and progesterone-receptor status were independent predictors of recurrence, they could be combined to stratify the cases further: breast cancer was found to have recurred in 11 of 12 patients (92 percent) who were positive for Hpr and negative for progesterone receptors, in 5 of 11 (45 percent) who were positive for Hpr and positive for progesterone receptors, and in 9 of 41 (22 percent) who were negative for Hpr, in whom progesterone-receptor status had little effect. We conclude that Hpr-epitope expression is a clinically important predictor of the recurrence of cancer in patients with early breast cancer, especially in combination with progesterone-receptor status.

Source Information

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.

This article has been cited by other articles:

• Yoon, S., Lee, M.-Y., Park, S. W., Moon, J.-S., Koh, Y.-K., Ahn, Y.-H., Park, B.-W., Kim, K.-S. (2007). Up-regulation of Acetyl-CoA Carboxylase {alpha} and Fatty Acid Synthase by Human Epidermal Growth Factor Receptor 2 at the Translational Level in Breast Cancer Cells. J. Biol. Chem. 282: 26122-26131 [Abstract] [Full Text]  
• Kinlaw, W. B., Quinn, J. L., Wells, W. A., Roser-Jones, C., Moncur, J. T. (2006). Spot 14: A Marker of Aggressive Breast Cancer and a Potential Therapeutic Target. Endocrinology 147: 4048-4055 [Abstract] [Full Text]  
• Menendez, J. A., Vellon, L., Lupu, R. (2005). Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann Oncol 16: 1253-1267 [Abstract] [Full Text]  
• Menendez, J. A., Vellon, L., Mehmi, I., Oza, B. P., Ropero, S., Colomer, R., Lupu, R. (2004). Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc. Natl. Acad. Sci. USA 101: 10715-10720 [Abstract] [Full Text]  
• Takahiro, T., Shinichi, K., Toshimitsu, S. (2003). Expression of Fatty Acid Synthase as a Prognostic Indicator in Soft Tissue Sarcomas. Clin. Cancer Res. 9: 2204-2212 [Abstract] [Full Text]  
• Kusakabe, T., Maeda, M., Hoshi, N., Sugino, T., Watanabe, K., Fukuda, T., Suzuki, T. (2000). Fatty Acid Synthase Is Expressed Mainly in Adult Hormone-sensitive Cells or Cells with High Lipid Metabolism and in Proliferating Fetal Cells. J. Histochem. Cytochem. 48: 613-622 [Abstract] [Full Text]  
• Moncur, J. T., Park, J. P., Memoli, V. A., Mohandas, T. K., Kinlaw, W. B. (1998). The "Spot 14" gene resides on the telomeric end of the 11q13 amplicon and is expressed in lipogenic breast cancers: Implications for control of tumor metabolism. Proc. Natl. Acad. Sci. USA 95: 6989-6994 [Abstract] [Full Text]  
• Muranjan, M., Nussenzweig, V., Tomlinson, S. (1998). Characterization of the Human Serum Trypanosome Toxin, Haptoglobin-related Protein. J. Biol. Chem. 273: 3884-3887 [Abstract] [Full Text]  
• (1989). A NEW PROGNOSTIC MARKER FOR BREAST CANCER. JWatch General 1989: 2-2 [Full Text]